The Retatrutide Guide
Source library

Scientific references

Primary trials, official registry records and selected sponsor reports used throughout The Retatrutide Guide.

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526.Peer-reviewed research
  2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised phase 2 trial. The Lancet. 2023;402:529–544.Peer-reviewed research
  3. ClinicalTrials.gov. TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight. NCT05929066. Record updated June 2026.Official trial registry
  4. ClinicalTrials.gov. TRIUMPH-3: Retatrutide in Participants With Obesity and Cardiovascular Disease. NCT05882045. Record updated May 2026.Official trial registry
  5. ClinicalTrials.gov. TRIUMPH-5: Retatrutide Compared With Tirzepatide in Adults With Obesity. NCT06662383.Official trial registry
  6. Eli Lilly and Company. TRIUMPH-1 Phase 3 topline results and American Diabetes Association 86th Scientific Sessions program update. May 2026.Sponsor report
  7. Eli Lilly and Company. TRANSCEND-T2D-1 Phase 3 topline results for retatrutide in type 2 diabetes. March 2026.Sponsor report
  8. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002.Peer-reviewed research
  9. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216.Peer-reviewed research
Editorial note

Journal citations and registry identifiers were verified before publication. Sponsor-reported 2026 results are labeled because publication and regulatory review are separate milestones.